Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · IEX Real-Time Price · USD
72.32
0.00 (0.00%)
At close: May 3, 2024, 4:00 PM
73.90
+1.58 (2.18%)
After-hours: May 3, 2024, 4:20 PM EDT
Ligand Pharmaceuticals Employees
Ligand Pharmaceuticals had 58 employees on December 31, 2023. The number of employees decreased by 18 or -23.68% compared to the previous year.
Employees
58
Change (1Y)
-18
Growth (1Y)
-23.68%
Revenue / Employee
n/a
Profits / Employee
n/a
Market Cap
1.33B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 58 | -18 | -23.68% |
Dec 31, 2022 | 76 | -78 | -50.65% |
Dec 31, 2021 | 154 | -1 | -0.65% |
Dec 31, 2020 | 155 | 40 | 34.78% |
Dec 31, 2019 | 115 | -1 | -0.86% |
Dec 31, 2018 | 116 | 77 | 197.44% |
Dec 31, 2017 | 39 | 17 | 77.27% |
Dec 31, 2016 | 22 | 1 | 4.76% |
Dec 31, 2015 | 21 | 2 | 10.53% |
Dec 31, 2014 | 19 | -1 | -5.00% |
Dec 31, 2013 | 20 | -1 | -4.76% |
Dec 31, 2012 | 21 | 0 | - |
Dec 31, 2011 | 21 | -10 | -32.26% |
Dec 31, 2010 | 31 | -41 | -56.94% |
Dec 31, 2009 | 72 | -24 | -25.00% |
Dec 31, 2008 | 96 | 37 | 62.71% |
Dec 31, 2007 | 59 | -63 | -51.64% |
Dec 31, 2006 | 122 | -371 | -75.25% |
Dec 31, 2005 | 493 | -26 | -5.01% |
Dec 31, 2004 | 519 | 58 | 12.58% |
Dec 31, 2003 | 461 | 59 | 14.68% |
Dec 31, 2002 | 402 | 51 | 14.53% |
Dec 31, 2001 | 351 | -5 | -1.40% |
Dec 31, 2000 | 356 | -29 | -7.53% |
Dec 31, 1999 | 385 | -33 | -7.89% |
Dec 31, 1998 | 418 | 73 | 21.16% |
Dec 31, 1997 | 345 | 16 | 4.86% |
Dec 31, 1996 | 329 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Pacira BioSciences | 712 |
Gyre Therapeutics | 593 |
Ironwood Pharmaceuticals | 267 |
4D Molecular Therapeutics | 147 |
Akero Therapeutics | 56 |
Belite Bio | 20 |
LGND News
- 11 days ago - Ligand to Report First Quarter 2024 Financial Results on May 7, 2024 - Business Wire
- 26 days ago - Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference - Business Wire
- 4 weeks ago - Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™ - Business Wire
- 2 months ago - Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference - Business Wire
- 2 months ago - Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Ligand Reports Fourth Quarter and Full Year 2023 Financial Results - Business Wire
- 2 months ago - Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa® - Business Wire
- 2 months ago - Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires - Business Wire